Mark I. Allenby

723 total citations
17 papers, 257 citations indexed

About

Mark I. Allenby is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Speech and Hearing. According to data from OpenAlex, Mark I. Allenby has authored 17 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 3 papers in Speech and Hearing. Recurrent topics in Mark I. Allenby's work include Cystic Fibrosis Research Advances (11 papers), Asthma and respiratory diseases (6 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Mark I. Allenby is often cited by papers focused on Cystic Fibrosis Research Advances (11 papers), Asthma and respiratory diseases (6 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Mark I. Allenby collaborates with scholars based in United Kingdom, United States and France. Mark I. Allenby's co-authors include Abhijat Sheth, Brendan Madden, Tuck-Kay Loke, Brian O’Connor, R.I. Ketchell, A. Wright, Philip Lumley, Gary Connett, Zoe L. Saynor and T. Daniels and has published in prestigious journals such as Journal of Applied Physiology, Journal of Allergy and Clinical Immunology and Thorax.

In The Last Decade

Mark I. Allenby

15 papers receiving 251 citations

Peers

Countries citing papers authored by Mark I. Allenby

Since Specialization

Citations

This map shows the geographic impact of Mark I. Allenby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark I. Allenby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark I. Allenby more than expected).

Fields of papers citing papers by Mark I. Allenby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark I. Allenby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark I. Allenby. The network helps show where Mark I. Allenby may publish in the future.

Co-authorship network of co-authors of Mark I. Allenby

This figure shows the co-authorship network connecting the top 25 collaborators of Mark I. Allenby. A scholar is included among the top collaborators of Mark I. Allenby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark I. Allenby. Mark I. Allenby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Cardiovascular function in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A cross-sectional, observational, single-centre study 2025 ·Journal of Cystic Fibrosis ·(unknown), Anthony I. Shepherd, Jo Corbett, Maria Perissiou, Gary Connett, Julian Legg, Mark I. Allenby, T. Daniels, Don S. Urquhart, Kelly A. Mackintosh, Melitta A. McNarry, Zoe L. Saynor	1
2	P097 Elevated liver function tests in infants exposed to elexacaftor/tezacaftor/ivacaftor in utero and while breastfeeding – case report series from 4 mother-infant pairs 2025 ·Journal of Cystic Fibrosis ·(unknown), Amanda Bevan, Julian Legg, Jay Self, Mark I. Allenby	0
3	Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study 2025 ·Pediatric Pulmonology ·(unknown), Anthony I. Shepherd, Jo Corbett, Mathieu Gruet, Gary Connett, Mark I. Allenby, Julian Legg, T. Daniels, Don S. Urquhart, Zoe L. Saynor	0
4	Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding – Case reports 2024 ·Journal of Cystic Fibrosis ·(unknown), Amanda Bevan, Julian Legg, Jay Self, Mark I. Allenby	1
5	The impact of plasma 25‐hydroxyvitamin D on pulmonary function and exercise physiology in cystic fibrosis: A multicentre retrospective study 2021 ·Journal of Human Nutrition and Dietetics ·Raquel Revuelta Iniesta, (unknown), (unknown), Gary Connett, Mark I. Allenby, T. Daniels, Mary P. Carroll, Don S. Urquhart, Zoe L. Saynor	3
6	Prospectively predicting Pseudomonas aeruginosa infection/s using routine data from the UK cystic fibrosis register 2021 ·Health Science Reports ·Nikki Totton, Mike Bradburn, Zhe Hui Hoo, (unknown), Daniel Hind, (unknown), E Shepherd, Julia A. Nightingale, T. Daniels, Jane Dewar, (unknown), Mary Carroll, Mark I. Allenby, F. Edenborough, (unknown), (unknown), Martin J Wildman	3
7	Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis 2020 ·Redox Biology ·(unknown), Janis K. Shute, Michael H. Cummings, Anthony I. Shepherd, Mathieu Gruet, Joseph T. Costello, Stephen J. Bailey, Martin R. Lindley, (unknown), Gary Connett, Mark I. Allenby, Mary P. Carroll, T. Daniels, Zoe L. Saynor	36
8	The implications of dysglycaemia on aerobic exercise and ventilatory function in cystic fibrosis 2019 ·Journal of Cystic Fibrosis ·(unknown), Janis K. Shute, Michael H. Cummings, Anthony I. Shepherd, (unknown), Mark I. Allenby, (unknown), (unknown), Mary P. Carroll, Gary Connett, T. Daniels, (unknown), Zoe L. Saynor	7
9	Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians’ decision 2018 ·European Journal of Clinical Microbiology & Infectious Diseases ·Zhe Hui Hoo, F. Edenborough, (unknown), Laura Prtak, Jane Dewar, Mark I. Allenby, Julia A. Nightingale, Martin J Wildman	14
10	Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis 2018 ·European Journal of Clinical Microbiology & Infectious Diseases ·Zhe Hui Hoo, Elizabeth Coates, Chin Maguire, Hannah Cantrill, Nadia Shafi, E.F. Nash, Angela McGowan, Stephen Bourke, W.G. Flight, (unknown), Julia A. Nightingale, Mark I. Allenby, (unknown), Martin J Wildman	3
11	Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of Vo_2max in people with cystic fibrosis: a retrospective analysis 2018 ·Journal of Applied Physiology ·(unknown), Janis K. Shute, Michael H. Cummings, Anthony I. Shepherd, (unknown), Gary Connett, Mark I. Allenby, Mary P. Carroll, T. Daniels, Zoe L. Saynor	20
12	155 CFHealthHub: using Leeds criteria and clinicians' decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study 2017 ·Journal of Cystic Fibrosis ·Zhe Hui Hoo, Simon Waterhouse, Julia A. Nightingale, Jane Dewar, Mark I. Allenby, (unknown), (unknown), Louis Evans, Chin Maguire, Hannah Cantrill, Martin J Wildman	4
13	IPD2.08 CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: An exploratory analysis of data from CFHealthHub two centre pilot trial 2017 ·Journal of Cystic Fibrosis ·Madelynne A Arden, (unknown), Julia A. Nightingale, Mark I. Allenby, Jane Dewar, (unknown), (unknown), (unknown), Martin J Wildman	5
14	A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease 2006 ·Vascular Pharmacology ·Brendan Madden, Mark I. Allenby, Tuck-Kay Loke, Abhijat Sheth	76
15	Inhalation challenge with low dose lipopolysaccharide is safe and well tolerated on healthy subjects 2003 ·Thorax ·Mark I. Allenby, (unknown), Jonathan Ratoff, Jeremy Ward, Leonard Tan, (unknown), (unknown), Brian O’Connor	1
16	The changes in airway inflammatory cells following inhalation of lipopolysaccharide (LPS) 2002 ·Journal of Allergy and Clinical Immunology ·Mark I. Allenby, (unknown), R.I. Ketchell, (unknown), (unknown), D.M. Kemeny, Brian O’Connor	4
17	Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5′-monophosphate in mild asthma 2002 ·Journal of Allergy and Clinical Immunology ·R.I. Ketchell, (unknown), Philip Lumley, A. Wright, Mark I. Allenby, Brian O’Connor	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact